Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2022-04-27 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
Earnings Release Classification · 100% confidence The document is explicitly labeled as an 'Ad-hoc' announcement released on April 27, 2022, and references 'Key word(s): Quarter Results'. It details business updates for the 'first-quarter' (Q1 2022), including sales figures, FDA clearances, clinical data updates, and milestone payments. This content structure—a summary of recent operational and financial highlights for a specific short period (a quarter) without being the full, detailed financial statement—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR), but rather the initial announcement of the period's results. Q1 2022
2022-04-27 English
Kuros Biosciencess MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as an 'Ad-hoc' announcement released on April 21, 2022, and states 'Release of an ad hoc announcement pursuant to Art. 53 LR'. It details a specific operational/regulatory event: FDA clearance for a product (MagnetOs Flex Matrix). This type of announcement, which is a material, non-scheduled disclosure of significant company news (like regulatory approvals or major product milestones), typically falls under general regulatory announcements or news releases that are not standard periodic reports (10-K, IR) or specific financial disclosures (ER, DIV). Since it is a significant, non-routine announcement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for a material, ad-hoc regulatory/operational update that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements.
2022-04-21 English
Kuros Biosciences reports results for the full year 2021
Earnings Release Classification · 96% confidence The document is explicitly titled 'Kuros Biosciences reports results for the full year 2021' and contains detailed 'Financial highlights' and 'Operational highlights' for the year ending December 31, 2021. It includes a summary of revenues, costs, net loss, and a detailed table of key financial figures comparing 2021 to 2020. This content structure strongly indicates a primary financial reporting document covering a full fiscal year. Although it is presented as an 'Ad-hoc' announcement (which might suggest ER or RNS), the depth and scope of the full-year financial data provided, including the explicit mention of the 'annual report 2021' being available elsewhere, classifies this specific release as the comprehensive summary of the annual results, which aligns best with the scope of an Annual Report (10-K) or a very detailed Earnings Release/Interim Report. Given the full-year scope and the detailed financial tables, it functions as the primary disclosure of annual results, making '10-K' (Annual Report) the most appropriate classification for the *content type*, even if the filing wrapper is an ad-hoc release. However, since this is a summary announcement of the full year results, and not the full 10-K document itself, 'ER' (Earnings Release) is often used for the initial comprehensive results announcement, even for annual figures, especially when the actual 10-K is linked separately. Since it covers the *full year* and is highly detailed, it surpasses a typical quarterly ER. Given the options, and recognizing this is the primary disclosure of the full year's performance, it is closest to an Earnings Release (ER) summarizing the annual performance, or potentially an Interim Report (IR) if the company reports semi-annually, but 'ER' is standard for major results announcements. Since it explicitly covers the 'full year 2021', it is the annual results disclosure. In many contexts, the detailed press release summarizing the annual results is classified as an Earnings Release (ER). I will select ER as it is the initial, detailed announcement of the annual results, distinct from the formal 10-K filing. FY 2021
2022-03-16 English
Kuros Biosciencess MagnetOs Granules cleared by FDA for expanded spinal indications
Regulatory Filings Classification · 95% confidence The document is a press release dated February 3, 2022, announcing that Kuros Biosciences' MagnetOs Granules received clearance from the U.S. Food and Drug Administration (FDA) for expanded spinal indications. It details the clinical trial evidence used for the clearance and includes standard sections like 'About MagnetOs', 'About Project Fusion', and 'Forward Looking Statements'. This type of announcement, which communicates a significant corporate event (regulatory clearance) but is not a formal regulatory filing like a 10-K or a detailed financial report like an IR, best fits the category for general corporate news or regulatory updates that don't fit elsewhere. Since it is a news announcement about a regulatory event, and not the regulatory filing itself, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for corporate news releases that don't match specific financial report types (like ER, IR, or CT). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to an attached report.
2022-02-03 English
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 20, 2022, announcing the publication of clinical data for a drug candidate (Fibrin-PTH) in a peer-reviewed journal (JBJS). It details Phase II trial results, compares them to standard of care, and discusses the implications for future development (spinal fusion). This type of announcement, focusing on clinical trial results and scientific updates, is characteristic of an Earnings Release (ER) if it were summarizing period results, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the content is a detailed scientific/clinical update rather than a summary of quarterly financial performance (ER) or a general regulatory filing (RNS), it most closely aligns with an announcement of significant operational/scientific progress. Since there is no specific category for 'Clinical Trial Result Announcement' and it is not a full report (10-K, IR), nor a presentation (IP), nor a management discussion (MDA), the most appropriate general category for a significant, non-financial operational update that is not a standard regulatory form is the general Regulatory Filings category (RNS), as it is a formal news release about a material event. However, if we strictly interpret the definitions, this is a news announcement about scientific progress, which often accompanies or precedes formal filings. Given the structure (News Details, Corporate announcement, CEO quote, contact info, boilerplate about the product/company), it functions as a press release. In the absence of a specific 'Clinical Update' category, RNS is the best fit for a formal, non-financial regulatory news item.
2022-01-20 English
Kuros Biosciences reports continued increase in MagnetOs U.S. sales
Earnings Release Classification · 100% confidence The document is explicitly labeled as an 'Ad-hoc announcement pursuant to Art. 53 LR' and is a brief news release providing an update on commercial activities (MagnetOs U.S. sales increase) and business progress, rather than a comprehensive financial report (like 10-K or IR) or a full transcript. It is a timely, material disclosure required by listing rules. Since it is a specific, material business update that doesn't fit the definitions for ER (Earnings Release, which focuses on period results), DIV, or CAP, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for required ad-hoc disclosures not covered by more specific codes. Given its nature as a mandatory, timely disclosure, RNS is the most appropriate fit among the provided options, although it shares characteristics with an ER summary. Q3 2021
2021-10-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.